198 related articles for article (PubMed ID: 8460927)
1. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.
Collins LA; Malanoski GJ; Eliopoulos GM; Wennersten CB; Ferraro MJ; Moellering RC
Antimicrob Agents Chemother; 1993 Mar; 37(3):598-601. PubMed ID: 8460927
[TBL] [Abstract][Full Text] [Related]
2. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria.
Shonekan D; Handwerger S; Mildvan D
J Antimicrob Chemother; 1997 Mar; 39(3):405-9. PubMed ID: 9096191
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.
Qadri SM; Ueno Y; Abu Mostafa FM; Halim M
Chemotherapy; 1997; 43(2):94-9. PubMed ID: 9084917
[TBL] [Abstract][Full Text] [Related]
5. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
6. Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.
Nicas TI; Cole CT; Preston DA; Schabel AA; Nagarajan R
Antimicrob Agents Chemother; 1989 Sep; 33(9):1477-81. PubMed ID: 2817848
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.
Collins LA; Eliopoulos GM; Wennersten CB; Ferraro MJ; Moellering RC
Antimicrob Agents Chemother; 1993 Jun; 37(6):1364-6. PubMed ID: 8328787
[TBL] [Abstract][Full Text] [Related]
8. [Susceptibilities of Enterococcus faecium, PRSP and MRSA to RP59500 and their correlations with those to other drugs].
Inoue M; Kubo S; Saito A; Ubukata K; Shimizu Y; Igari J; Watanabe A; Oguri T; Kawai T; Kobayashi Y; Hayashi M; Shiba K; Sakamoto M; Kanno H; Tokue Y; Yamaguchi K; Miyazaki S; Higashitsutsumi M; Sakamoto M; Inamatsu T; Kohno S; Tomono K; Shimada J; Kaku M; Ueda Y
Jpn J Antibiot; 1999 Apr; 52(4):302-12. PubMed ID: 10396687
[TBL] [Abstract][Full Text] [Related]
9. In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group.
Putnam SD; Jones RN; Johnson DM
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):139-47. PubMed ID: 9294704
[TBL] [Abstract][Full Text] [Related]
10. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
Williams JD; Maskell JP; Whiley AC; Sefton AM
J Antimicrob Chemother; 1997 May; 39 Suppl A():41-6. PubMed ID: 9511061
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.
Jamjian C; Biedenbach DJ; Jones RN
Antimicrob Agents Chemother; 1997 Feb; 41(2):454-9. PubMed ID: 9021207
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
Jensen KT; Schønheyder H; Pers C; Thomsen VF
APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria.
Malathum K; Coque TM; Singh KV; Murray BE
Antimicrob Agents Chemother; 1999 Apr; 43(4):930-6. PubMed ID: 10103202
[TBL] [Abstract][Full Text] [Related]
14. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Zweifel MJ; Wilkie SC; Rodriguez MJ; Thompson RC; Cooper RD
Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
[TBL] [Abstract][Full Text] [Related]
15. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
Finch RG
Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
[TBL] [Abstract][Full Text] [Related]
17. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
King A; Phillips I
J Antimicrob Chemother; 2001 Aug; 48(2):219-23. PubMed ID: 11481291
[TBL] [Abstract][Full Text] [Related]
18. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
Luh KT; Hsueh PR; Teng LJ; Pan HJ; Chen YC; Lu JJ; Wu JJ; Ho SW
Antimicrob Agents Chemother; 2000 Dec; 44(12):3374-80. PubMed ID: 11083643
[TBL] [Abstract][Full Text] [Related]
19. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.
Freeman C; Robinson A; Cooper B; Mazens-Sullivan M; Quintiliani R; Nightingale C
Diagn Microbiol Infect Dis; 1995 Jan; 21(1):47-50. PubMed ID: 7789096
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium.
Ristow TA; Noskin GA; Warren JR; Peterson LR
Microb Drug Resist; 1995; 1(4):335-9. PubMed ID: 9158806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
